KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

A Phase 3 Study of the Safety and Efficacy of Tedizolid Phosphate in Patients <12 Years of Age With Acute Bacterial Skin and Skin Structure Infections.

Rosie Mngqibisa, Oleksandr Fofanov, Carlos F Grazioso, Mario Melgar Toledo, Melissa Boddicker, Natalya Broyde, Sandra Koseoglu, Lizbeth Romero, Mara Stevens, Pamela Sears

Pediatr Infect Dis J 44(6) 533-538

PMID40233296
PMCIDPMC12058361
DOI10.1097/INF.0000000000004807
发表日期2025-04-15
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: Acute bacterial skin and skin structure infections (ABSSSI) are serious infections of the skin and subcutaneous tissue that include major cutaneous abscesses, cellulitis/erysipelas, and wound infections. ABSSSI caused by Gram-positive pathogens are common in children, who tend to experience high rates of morbidity and hospitalization due to ABSSSI, including those caused by antibacterial-resistant pathogens. METHODS: This phase 3 study (NCT03176134) investigated the safety of tedizolid phosphate and its ability to treat ABSSSI in pediatric participants 28 days to <12 years of age. A total of 100 participants were randomized 3:1 to intravenous and/or oral tedizolid phosphate for 6-10 days or intravenous and/or oral comparator for 10-14 days; participants were stratified and enrolled by age cohort. The primary objective was to evaluate the safety of tedizolid phosphate versus comparators using descriptive statistics. The secondary objective was to evaluate clinical response at the test-of-cure (TOC) visit in the intent-to-treat and clinically evaluable populations. RESULTS: Tedizolid phosphate was well tolerated, and adverse events were comparable between the tedizolid phosphate and comparator groups. Clinical success rates at the TOC visit in the intent-to-treat and clinically evaluable populations were high (>90%) and comparable between groups. All participants in the tedizolid phosphate treatment group who had skin culture results at baseline experienced favorable microbiological response at the TOC visit. CONCLUSIONS: The results of this study provide evidence to support the use of tedizolid phosphate to treat ABSSSI caused by Gram-positive pathogens in pediatric patients from 28 days to <12 years of age.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。